Zimislecel (VX-880) is an investigational stem cell-derived islet cell therapy for T1D patients with severe hypoglycemia and impaired awareness. It aims to restore insulin production and glucose regulation. Delivered via hepatic portal vein infusion, it requires immunosuppression and holds multiple regulatory designations across the US, Europe, and the UK.
At ADA 2025, Zimislecel showed durable benefits in T1D patients; 10 of 12 were insulin-free after one year, all met HbA1c <7% and >70% time-in-range.
At the American Diabetes Association (ADA) annual conference in Chicago, Vertex Pharmaceuticals shared encouraging results for Zimislecel in T1D, w...
